BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients.

The clinical course of 50 patients with low-grade glioma (31 male, 19 female) undergoing surgery at a single Institution from 1992 to 1996 was analyzed in relationship with known prognostic factors as far as time to tumor progression (TTP) and survival time (ST) are concerned.

Histology revealed 11 fibrillary, 6 protoplasmatic, 5 gemistocytic astrocytoma, 18 oligoastrocytoma and 10 oligodendroglioma.

Of the remaining 46, twenty-four have shown disease progression and 14 have died.

Complete gross tumor removal was associated to a longer TTP (P = 0.04 logrank).

Of the investigated immunohistochemical parameters, while MVD was not predictive of subsequent TTP, expression of CXCL12 was associated with a significantly shorter TTP (P = 0.01 logrank): this predictive value remained significant (P = 0.02) at multivariate analysis.

The data suggest the possible prognostic value for CXCL-12 (an angiogenesis- and tumor-growth-related chemokine) on TTP in low-grade gliomas.

[MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Chemokines, CXC / biosynthesis. Glioma / metabolism

[MeSH-minor] Adult. Aged. Chemokine CXCL12. Child. Child, Preschool. Disease Progression. Disease-Free Survival. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Prognosis. Treatment Outcome

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Cancer Res. 2000 Jan;6(1):102-11 [10656438.001]

[Cites] Acta Neurochir (Wien). 1998;140(12):1213-22 [9932120.001]

[Cites] J Neurooncol. 2004 May;67(3):305-17 [15164986.001]

[Cites] Cancer Res. 2003 Apr 15;63(8):1969-74 [12702590.001]

[Cites] Brain Pathol. 2003 Apr;13(2):176-84 [12744471.001]

[Cites] Surg Neurol. 1995 Sep;44(3):208-21; discussion 221-3 [8545771.001]

[Cites] J Biol Chem. 2002 Dec 20;277(51):49481-7 [12388552.001]

[Cites] J Neurosurg. 1998 Mar;88(3):513-20 [9488306.001]

[Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]

[Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):911-4 [9276354.001]

[Cites] J Neurooncol. 2000 Aug;49(1):71-5 [11131989.001]

[Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]

[Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):319-31 [10931365.001]

[Cites] Br J Neurosurg. 2001 Jun;15(3):247-50 [11478061.001]

[Cites] J Neurooncol. 1997 Feb;31(3):273-8 [9049856.001]

[Cites] Cancer. 1996 Apr 15;77(8):1535-43 [8608540.001]

[Cites] J Neurooncol. 2002 Sep;59(3):231-7 [12241120.001]

[Cites] Oncology. 2000 Feb;58(2):108-16 [10705237.001]

[Cites] J Neurooncol. 1999;45(2):117-25 [10778727.001]

[Cites] Surg Neurol. 2000 Sep;54(3):229-34; discussion 234 [11118569.001]

[Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):23-8 [14765381.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]

[Cites] J Neuropathol Exp Neurol. 1999 Jan;58(1):46-53 [10068313.001]

[Cites] Ann Neurol. 2002 Dec;52(6):842-5 [12447941.001]

[Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]

(PMID = 16132525.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Temozolomide (TMZ) is an alkylating agent earlier approved for recurrent anaplastic astrocytoma and approved for the treatment of newly diagnosed glioblastoma in the USA and Europe in 2005.

The early preliminary evidence for activity in recurrent malignant gliomas further resulted in a broad evaluation of TMZ for other tumors in neuro-oncology, mainly low-grade gliomas, brain metastases and primary cerebral lymphomas.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DACARBAZINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16556052.001).

[ISSN] 1479-6694

[Journal-full-title] Future oncology (London, England)

[ISO-abbreviation] Future Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide

[Number-of-references] 31

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma.

BACKGROUND: In patients with high grade glioma, little is known regarding existence of naturally occurring adaptive T cell reactivity against glioma-associated antigens (GAAs).

In this report, we characterized GAA-specific CD8+ T cells and innate immune cells in a patient who has survived with anaplastic astrocytoma (AA) for over 12 years without recurrence.

RESULTS: The patient's tumor expressed both EphA2 and IL-13Ralpha2, and in vitro stimulated PBMC demonstrated superior EphA2883-891 and IL-13Ralpha2345-353-specific CTL reactivity compared to PBMC samples from two other patients with progressing malignant glioma.

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]

[Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]

[Cites] Cancer. 2000 Feb 1;88(3):577-83 [10649250.001]

[Cites] Cancer Res. 2000 Sep 1;60(17):4946-52 [10987311.001]

[Cites] J Cell Biol. 2001 Mar 5;152(5):971-84 [11238453.001]

[Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):909s-916s [11300491.001]

[Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]

[Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]

[Cites] Brain Res Brain Res Rev. 2003 May;42(2):97-122 [12738053.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8874-9 [12847287.001]

[Cites] J Immunol. 2003 Nov 1;171(9):4927-33 [14568975.001]

[Cites] Clin Cancer Res. 2004 Oct 15;10(20):6946-55 [15501973.001]

[Cites] J Exp Med. 1998 Nov 2;188(9):1641-50 [9802976.001]

[Cites] Nat Med. 1999 Jun;5(6):677-85 [10371507.001]

[Cites] Cancer Res. 1999 Aug 15;59(16):4050-5 [10463606.001]

[Cites] Cancer Res. 2004 Nov 1;64(21):8062-7 [15520217.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]

[Cites] Int J Cancer. 2005 Jun 20;115(3):450-5 [15688371.001]

[Cites] J Immunol. 2005 Jun 1;174(11):6863-71 [15905528.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6 [15980149.001]

[Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]

[Cites] Cancer Res. 2006 May 1;66(9):4943-51 [16651452.001]

[Cites] Cancer Res. 2006 Jun 1;66(11):5883-91 [16740728.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]

[Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]

[Cites] J Invest Dermatol. 2007 Mar;127(3):622-9 [17039243.001]

[Cites] Cancer Res. 2007 Feb 15;67(4):1842-52 [17293384.001]

[Cites] J Clin Invest. 2007 May;117(5):1204-12 [17476350.001]

[Cites] Cancer. 2007 Jul 1;110(1):203-14 [17541944.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] Nat Med. 2007 Sep;13(9):1050-9 [17704786.001]

[Cites] Cancer Immunol Immunother. 2007 Dec;56(12):1931-43 [17522860.001]

(PMID = 18093336.001).

[ISSN] 1479-5876

[Journal-full-title] Journal of translational medicine

[ISO-abbreviation] J Transl Med

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P01 CA100327; United States / NINDS NIH HHS / NS / P01 NS040923; United States / NINDS NIH HHS / NS / P01 NS40923

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen

[Other-IDs] NLM/ PMC2244605

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas.

OBJECTIVE: The uptake of L-methyl-11C-methionine (MET) by gliomas is greater than that by intact tissue, making methionine very useful for evaluation of tumor extent.

METHODS: We performed this study on 67 glioma patients between 3 and 69 years of age (36 males and 31 females).

Tumors included diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, ependymoma, oligodendroglioma, medulloblastoma, dysembryoplastic neuroepithelial tumor, choroid plexus papilloma, central neurocytoma, optic glioma, gliomatosis cerebri, pleomorphic xanthoastrocytoma, and ganglioglioma.

Tumor activity and degree of malignancy were evaluated using Ki-67LI (LI: labeling index) and Kaplan-Meier survival curves.

The correlations between methionine uptake and tumor proliferation (tumor versus contralateral gray matter ratio (T/N) and Ki-67LI) were determined for the group of all subjects.

The existence of significant correlations between T/N and Ki-67LI and between SUV and Ki-67LI was determined for astrocytic tumors.

Receiver operating characteristics (ROC) analysis of T/N and standardized uptake value (SUV) was performed for the group of astrocytic tumors.

RESULTS: For the 67 cases of glioma, the degree of accumulation was variable.

Ki-67LI differed significantly between the high-grade group and low-grade group at T/N levels between 1.5 and 1.8 on analysis using tumor proliferative potential (p = 0.019-0.031).

The prognosis differed significantly between the high-grade and low-grade groups when T/N was in the range of 1.6-1.8 (p = 0.028-0.032).

CONCLUSIONS: When analysis was confined to cases of astrocytic tumor, a correlation was noted between methionine accumulation and Ki-67LI.

For the astrocytic tumors, T/N ratio seemed to be more useful as a diagnostic indicator than SUV.

The cut-off level of T/N ratio for distinction between high-grade and low-grade astrocytoma appears to lie between 1.5 and 1.6.

[MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radionuclide imaging. Glioma / pathology. Glioma / radionuclide imaging. Methionine / pharmacokinetics. Positron-Emission Tomography / methods

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

Hazardous Substances Data Bank. (L)-Methionine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16444993.001).

[ISSN] 0914-7187

[Journal-full-title] Annals of nuclear medicine

[ISO-abbreviation] Ann Nucl Med

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Radiopharmaceuticals; 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Diffusion tensor imaging of the white matter tracts in preoperative patients with cerebral neoplasm].

METHODS: Four female and 8 male patients aged from 21 to 62 years with brain malignancies (2 malignant lymphomas, 2 low-grade astrocytomas, and 8 high-grade cerebral gliomas) underwent conventional contrast-enhanced MR and DTI examinations before operation.

The DTI patterns in WMT altered by the tumor were categorized on the basis of FA1/FA2 ratio as follows: pattern 1, FA1/FA2> or =75% with normal or only slightly decreased FA; pattern 2, 50%< or =FA1/FA2<75% with WMT displacement; pattern 3, 25%< or =FA1/FA2/50% with WMT involvement; pattern 4, FA1/FA2<25% with WMT destruction.

CONCLUSIONS: DTI allows for visualization of WMT and benefits surgical planning for patients with intrinsic brain tumor.

There is a positive relationship between the bilateral FA ratio (FA1/FA2) variation and WMT alterations resulting from the tumor.

[MeSH-minor] Adult. Female. Glioblastoma / diagnosis. Glioma / diagnosis. Humans. Male. Middle Aged. Nerve Fibers / radiography. Neural Pathways / radiation effects. Preoperative Care. Reproducibility of Results. Sensitivity and Specificity

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17121724.001).

[ISSN] 1673-4254

[Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University

[ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Natural history and management of brainstem gliomas in adults. A retrospective Italian study.

Brainstem gliomas in adults are rare tumors, with heterogeneous clinical course; only a few studies in the MRI era describe the features in consistent groups of patients.

In this retrospective study, we report clinical features at onset, imaging characteristics and subsequent course in a group of 34 adult patients with either histologically proven or clinico-radiologically diagnosed brainstem gliomas followed at two centers in Northern Italy.

In 21 of the patients histology was obtained and in 20 it was informative (2 pilocytic astrocytoma, 9 low-grade astrocytoma, 8 anaplastic astrocytoma and 1 glioblastoma).

Only minor radiological responses were observed after treatments; in a significant proportion of patients (9 out of 15) clinical improvement during therapy occurred in the context of radiologically (MRI) stable disease.

Grade III or IV myelotoxicity was observed in 6 patients.

After a follow-up ranging from 9 to 180 months, all but 2 patients have progressed and 14 have died (12 for disease progression, 2 for pulmonary embolism).

Investigation of putative prognostically relevant parameters showed that a short time between disease onset and diagnosis was related to a shorter survival.

Compared with literature data, our study confirms the clinical and radiological heterogeneity of adult brainstem gliomas and underscores the need for multicenter trials in order to assess the efficacy of treatments in these tumors.

[MeSH-major] Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / therapy. Glioma / pathology. Glioma / therapy

[MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain / pathology. Disease Progression. Female. Fluorodeoxyglucose F18. Humans. Image Processing, Computer-Assisted. Italy. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals. Retrospective Studies. Spinal Cord / pathology. Survival Analysis. Treatment Outcome

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurosurg. 2006 Feb;104(2 Suppl):108-14 [16506498.001]

[Cites] Curr Opin Neurol. 2001 Dec;14(6):711-5 [11723378.001]

[Cites] Neurosurg Rev. 2005 Oct;28(4):330-2 [16001287.001]

[Cites] Acta Neurochir Suppl (Wien). 1991;53:148-58 [1803873.001]

[Cites] Brain. 2001 Dec;124(Pt 12):2528-39 [11701605.001]

[Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):20-31 [15850898.001]

[Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):235-41 [8420871.001]

[Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]

[Cites] J Clin Oncol. 2006 Mar 10;24(8):1266-72 [16525181.001]

[Cites] Neurology. 1998 Oct;51(4):1136-9 [9781543.001]

[Cites] Acta Neurochir (Wien). 1986;79(2-4):67-73 [3962745.001]

[Cites] Cancer. 2005 Jan 1;103(1):133-9 [15565574.001]

[Cites] Neurochirurgie. 1989;35(1):41-6 [2654682.001]

[Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):757-60 [2004952.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]

(PMID = 18293027.001).

[ISSN] 0340-5354

[Journal-full-title] Journal of neurology

[ISO-abbreviation] J. Neurol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Surveillance imaging strategies following surgery and/or radiotherapy for childhood cerebellar low-grade astrocytoma.

OBJECT: The authors sought to evaluate surveillance strategies for the detection and monitoring of residual and recurrent disease in children with cerebellar low-grade astrocytomas (CLGAs) treated surgically or with radiotherapy.

(2) those with residual disease with no immediate adjuvant therapy; and (3) those who received radiotherapy for residual/recurrent disease.

Eighty-four children were followed for a mean period of 73 months (range 2-159 months).

Following an incomplete resection, radiologically detected tumor progression leading to further treatment was detected at 7, 9, 12, 13, and 20 months, respectively, and an additional six tumors regressed or stablized.

For follow up of residual tumor, 6-month interval imaging for at least 3 years, yearly images for another 2 years, and subsequent 2-year imaging is recommended.

[MeSH-major] Astrocytoma / diagnosis. Cerebellar Neoplasms / diagnosis. Magnetic Resonance Imaging. Neoplasm, Residual / diagnosis. Tomography, X-Ray Computed

[MeSH-minor] Adolescent. Cerebellum / pathology. Cerebellum / radiography. Cerebellum / surgery. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Postoperative Care. Remission, Spontaneous. Time Factors

Genetic Alliance. consumer health - Cerebellar Astrocytoma, Childhood.

MedlinePlus Health Information. consumer health - CT Scans.

MedlinePlus Health Information. consumer health - MRI Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16156227.001).

[ISSN] 0022-3085

[Journal-full-title] Journal of neurosurgery

[ISO-abbreviation] J. Neurosurg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Combined fontanelle puncture and surgical operation in treatment of desmoplastic infantile astrocytoma: case report and a review of the literature.

Desmoplastic infantile astrocytoma is a rare low-grade malignant brain tumor found in infants.

A case of desmoplastic infantile astrocytoma, including its clinical manifestations, pathological characteristics, differential diagnosis, treatment, and prognosis, is reported.

[MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Cranial Fontanelles / surgery. Neurosurgical Procedures / methods

Genetic Alliance. consumer health - Desmoplastic Infantile Astrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for desmoplastic infantile astrocytoma .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19671888.001).

[ISSN] 1708-8283

[Journal-full-title] Journal of child neurology

[ISO-abbreviation] J. Child Neurol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 9

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Altered cellular distribution and subcellular sorting of gamma-tubulin in diffuse astrocytic gliomas and human glioblastoma cell lines.

Centrosome amplification is a pivotal mechanism underlying tumorigenesis but its role in gliomas is underinvestigated.

The present study specifically examines the expression and distribution of the centrosome-associated cytoskeletal protein gamma-tubulin in 56 primary diffuse astrocytic gliomas (grades II-IV) and in 4 human glioblastoma cell lines (U87MG, U118MG, U138MG, and T98G).

In tumors in adults (n = 46), varying degrees of localization were detected in all tumor grades, but immunoreactivity was significantly increased in high-grade anaplastic astrocytomas and glioblastomas multiforme as compared to low-grade diffuse astrocytomas (p = 0.0001).

A similar trend was noted in diffuse gliomas in children but the sample of cases was too small as to be statistically meaningful.

Our results indicate that overexpression and ectopic cellular distribution of gamma-tubulin in astrocytic gliomas may be significant in the context of centrosome protein amplification and may be linked to tumor progression and anaplastic potential.

[MeSH-minor] Antigens / metabolism. Blotting, Northern / methods. Cell Line, Tumor. Humans. Immunohistochemistry / methods

Genetic Alliance. consumer health - Glioblastoma.

COS Scholar Universe. author profiles.

antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16772870.001).

[ISSN] 0022-3069

[Journal-full-title] Journal of neuropathology and experimental neurology

[ISO-abbreviation] J. Neuropathol. Exp. Neurol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens; 0 / Tubulin; 0 / pericentrin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic.

BACKGROUND: Low-grade gliomas (LGGs) are uncommon in older patients, and long-term clinical behavior and prognostic factors are not well defined in this group.

METHODS: The authors retrospectively searched their tumor registry for the records of adult patients (> or =18 years) diagnosed as having nonpilocytic LGG between 1960 and 1992 at Mayo Clinic.

Operative pathologic diagnoses comprised astrocytoma (n = 22, 69%), mixed oligoastrocytoma (n = 7, 22%), and oligodendroglioma (n = 3, 9%).

Pathologic sampling error failing to recognize higher-grade tumors does not seem to account for these poor outcomes.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]

[Cites] J Clin Oncol. 1997 Sep;15(9):3129-40 [9294476.001]

[Cites] Cancer. 2005 Mar 15;103(6):1227-33 [15690327.001]

[Cites] J Clin Oncol. 2005 Apr 1;23(10):2372-7 [15800329.001]

[Cites] Lancet. 2005 Sep 17-23;366(9490):985-90 [16168780.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]

[Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]

[Cites] Neurology. 2007 May 22;68(21):1831-6 [17515545.001]

[Cites] Brain Pathol. 2007 Jul;17(3):308-13 [17598823.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] J Clin Oncol. 2008 Mar 10;26(8):1338-45 [18323558.001]

[Cites] Neurosurgery. 2008 Oct;63(4):700-7; author reply 707-8 [18981880.001]

[Cites] J Neurooncol. 2008 Dec;90(3):341-50 [18682893.001]

[Cites] Neuro Oncol. 2009 Aug;11(4):437-45 [19018039.001]

[Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]

[Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]

[Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]

[Cites] J Neurosurg. 2000 Jun;92(6):983-90 [10839259.001]

[Cites] Strahlenther Onkol. 2000 Jun;176(6):259-64 [10897252.001]

[Cites] Neurology. 2001 Mar 13;56(5):618-23 [11245713.001]

[Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]

[Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]

[Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]

[Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]

[Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]

[Cites] J Neurooncol. 2003 Jul;63(3):305-12 [12892238.001]

[Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):117-25 [15093907.001]

[Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]

[Cites] Cancer. 1975 Nov;36(5):1681-9 [172217.001]

[Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]

[Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]

[Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]

[Cites] Cancer. 1981 Feb 15;47(4):649-52 [6164465.001]

[Cites] Br J Clin Pharmacol. 1982 Sep;14(3):325-31 [6751362.001]

[Cites] J Neurosurg. 1984 Oct;61(4):665-73 [6470776.001]

[Cites] Neurosurgery. 1987 Jun;20(6):975-82 [3614580.001]

[Cites] Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):837-41 [3141317.001]

[Cites] Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):663-8 [2921165.001]

[Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]

[Cites] Neurosurgery. 1989 May;24(5):686-92 [2716976.001]

[Cites] J Neurosurg. 1989 Oct;71(4):487-93 [2552044.001]

[Cites] Arch Neurol. 1989 Nov;46(11):1238-9 [2818260.001]

[Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1351-6 [2689399.001]

[Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]

[Cites] Ann Neurol. 1992 Apr;31(4):431-6 [1586143.001]

[Cites] Neurosurgery. 1993 Apr;32(4):554-9 [8474646.001]

[Cites] W V Med J. 1993 Mar;89(3):102-5 [8475621.001]

[Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]

[Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]

[Cites] Int J Radiat Oncol Biol Phys. 1993 May 20;26(2):239-44 [8387988.001]

[Cites] Acta Neurochir (Wien). 1993;123(1-2):1-7 [8213272.001]

[Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]

[Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112 [7677836.001]

[Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]

[Cites] J Neurooncol. 1997 Feb;31(3):273-8 [9049856.001]

[Cites] Surg Neurol. 1995 Sep;44(3):208-21; discussion 221-3 [8545771.001]

[Cites] J Neurooncol. 1996 Feb;27(2):173-7 [8699240.001]

[Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]

[Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]

[Cites] Neurology. 1999 Mar 10;52(4):867-9 [10078745.001]

(PMID = 19536875.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / UL1 RR024150; None / None / / UL1 RR024150-01; United States / NCRR NIH HHS / RR / 1 UL1 RR024150-01; United States / NCRR NIH HHS / RR / UL1 RR024150-01

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Other-IDs] NLM/ NIHMS140676; NLM/ PMC2789453

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Role of perfusion-weighted imaging at 3 Tesla in the assessment of malignancy of cerebral gliomas.

PURPOSE: This study was performed to clarify the role of perfusion-weighted imaging (PWI) at 3 Tesla in the characterisation of haemodynamic heterogeneity within gliomas and surrounding tissues and in the differentiation of high-grade from low-grade gliomas.

MATERIALS AND METHODS: We examined 36 patients with histologically verified gliomas (25 with high-grade and 11 with low-grade gliomas).

RESULTS: In high-grade gliomas, rCBV were markedly increased in mass [mean+/-standard deviation (SD), 4.3+/-1.2] and margins (4.0+/-1.1) and reduced in necrotic areas (0.3+/-0.3).

In low-grade gliomas, mass (2.0+/-1.5) and margin (2.2+/-1.2) rCBV were significantly lower than in high-grade gliomas (p<0.001).

CONCLUSIONS: Three-Tesla PWI helps to distinguish necrosis from tumour mass, infiltrating tumour from oedema and high-grade from low-grade gliomas.

It enhances the magnetic resonance (MR) assessment of cerebral gliomas and provides useful information for planning surgical and radiation treatment.

[MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods

[MeSH-minor] Adult. Aged. Astrocytoma / diagnosis. Blood Volume / physiology. Brain Edema / diagnosis. Cerebrovascular Circulation / physiology. Contrast Media. Diagnosis, Differential. Echo-Planar Imaging / methods. Female. Gadolinium DTPA. Ganglioglioma / diagnosis. Glioblastoma / diagnosis. Humans. Image Enhancement / methods. Male. Middle Aged. Necrosis. Oligodendroglioma / diagnosis. Retrospective Studies

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - MRI Scans.

Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21 [14970020.001]

[Cites] Neuroradiology. 2003 Apr;45(4):205-11 [12687302.001]

[Cites] J Magn Reson Imaging. 2006 Oct;24(4):817-24 [16958061.001]

[Cites] Radiology. 2002 Apr;223(1):11-29 [11930044.001]

[Cites] J Magn Reson Imaging. 2001 Apr;13(4):496-520 [11276094.001]

[Cites] Radiol Med. 2003 Mar;105(3):141-9 [12835637.001]

[Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]

[Cites] Radiology. 2005 Mar;234(3):869-77 [15665227.001]

[Cites] Magn Reson Imaging Clin N Am. 2006 Feb;14(1):77-88 [16530636.001]

[Cites] Radiol Med. 2002 Jul-Aug;104(1-2):87-91 [12386559.001]

[Cites] Cancer. 2004 Nov 15;101(10):2293-9 [15476282.001]

[Cites] Eur J Radiol. 2003 Dec;48(3):244-51 [14652141.001]

[Cites] Radiology. 2002 Mar;222(3):715-21 [11867790.001]

[Cites] AJNR Am J Neuroradiol. 2005 Oct;26(9):2187-99 [16219821.001]

[Cites] Radiol Med. 2003 Mar;105(3):150-61 [12835638.001]

[Cites] AJNR Am J Neuroradiol. 2004 May;25(5):746-55 [15140713.001]

[Cites] Surg Neurol. 1998 Apr;49(4):436-40 [9537664.001]

[Cites] J Neurosurg. 1995 Oct;83(4):682-9 [7674019.001]

[Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]

[Cites] Invest Radiol. 2003 Jul;38(7):385-402 [12821852.001]

[Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87 [16551981.001]

[Cites] AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32 [15502131.001]

[Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]

[Cites] Oncologist. 2004;9(5):528-37 [15477637.001]

[Cites] Eur Radiol. 2006 Jan;16(1):180-6 [16402258.001]

[Cites] Neuroradiology. 2004 Aug;46(8):619-27 [15243726.001]

[Cites] AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67 [16611779.001]

[Cites] Clin Radiol. 2003 Jul;58(7):505-13 [12834633.001]

[Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]

(PMID = 18338133.001).

[ISSN] 0033-8362

[Journal-full-title] La Radiologia medica

[ISO-abbreviation] Radiol Med

[Language] eng; ita

[Publication-type] Journal Article

[Publication-country] Italy

[Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Low-grade gliomas: the debate continues.

Low-grade gliomas (LGG) are a heterogeneous group of tumors that tend to occur primarily in young adults and children.

Many questions remain in the management of LGGs, including the role of surgical resection (ie, maximal tumor resection), the optimal timing of radiation (ie, postoperative vs at the time of tumor progression), and the role of chemotherapy (ie, salvage after radiotherapy, primary treatment after surgery, concurrent with radiotherapy).

[MeSH-major] Astrocytoma / pathology. Astrocytoma / therapy. Brain Neoplasms / pathology. Brain Neoplasms / therapy

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Lancet. 2002 Nov 2;360(9343):1361-8 [12423981.001]

[Cites] Ann Oncol. 2003 Dec;14 (12 ):1722-6 [14630675.001]

[Cites] Ann Neurol. 1992 Apr;31(4):431-6 [1586143.001]

[Cites] Neurology. 2005 Jun 28;64(12):2085-9 [15985578.001]

[Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]

[Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):527-33 [8655376.001]

[Cites] Brain Pathol. 2003 Apr;13(2):176-84 [12744471.001]

[Cites] J Clin Oncol. 2003 Oct 1;21(19):3710 [14512412.001]

[Cites] Eur Radiol. 2004 Nov;14(11):2061-6 [15252748.001]

[Cites] Semin Oncol. 2004 Oct;31(5):702-13 [15497124.001]

[Cites] J Neurosurg. 1993 Oct;79(4):533-6 [8410222.001]

[Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]

[Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]

[Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]

[Cites] J Clin Oncol. 2003 Jan 15;21(2):251-5 [12525516.001]

[Cites] Clin Radiol. 2005 Apr;60(4):493-502 [15767107.001]

[Cites] J Neurosurg. 1992 Feb;76(2):179-83 [1730945.001]

[Cites] J Neurooncol. 2004 Jul;68(3):263-74 [15332331.001]

[Cites] Neurology. 2001 Mar 13;56(5):618-23 [11245713.001]

[Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]

[Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]

[Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]

[Cites] J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):845-51 [15897509.001]

[Cites] Cancer. 2005 Mar 15;103(6):1227-33 [15690327.001]

[Cites] Mayo Clin Proc. 1987 Jun;62(6):450-9 [3553757.001]

[Cites] J Neurooncol. 1997 Feb;31(3):273-8 [9049856.001]

[Cites] Neurology. 2002 Jul 9;59(1):40-8 [12105305.001]

[Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]

[Cites] AJR Am J Roentgenol. 1986 Jul;147(1):119-24 [3487203.001]

[Cites] J Neurosurg. 1989 Apr;70(4):568-72 [2926497.001]

[Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]

[Cites] Ann Oncol. 2003 Dec;14 (12 ):1715-21 [14630674.001]

[Cites] Lancet. 2005 Sep 17-23;366(9490):985-90 [16168780.001]

[Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):374-9 [15667955.001]

[Cites] Neuro Oncol. 2003 Jul;5(3):161-7 [12816722.001]

[Cites] Neurology. 2003 Apr 8;60(7):1113-8 [12682316.001]

[Cites] J Neurooncol. 1996 Oct;30(1):61-9 [8865004.001]

[Cites] Radiother Oncol. 1996 Oct;41(1):55-9 [8961368.001]

[Cites] Strahlenther Onkol. 2004 Jul;180(7):408-18 [15241528.001]

[Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):117-25 [15093907.001]

[Cites] Neurochirurgia (Stuttg). 1992 Jan;35(1):18-22 [1570044.001]

[Cites] Neurology. 2001 May 22;56(10):1285-90 [11376174.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]

[Cites] Ann Neurol. 1990 Dec;28(6):818-22 [2178330.001]

[Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]

[Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]

[Cites] J Neurooncol. 2004 Feb;66(3):333-9 [15015665.001]

(PMID = 16566078.001).

[ISSN] 1523-3790

[Journal-full-title] Current oncology reports

[ISO-abbreviation] Curr Oncol Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 54

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Our cases demonstrate the morphological features of the 'rosette-forming glioneuronal tumour of the fourth ventricle', a recently identified tumour characterised by its unique location, neurocytic pseudo-rosette formation and the presence of a low grade astrocytoma component.

However, the clinical data available including the cases presented here, along with the histological features, suggest that these are low grade tumours with a good prognosis after surgical resection.

[MeSH-minor] Adult. Astrocytoma / metabolism. Astrocytoma / pathology. Astrocytoma / physiopathology. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neurocytoma / metabolism. Neurocytoma / pathology. Neurocytoma / physiopathology

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16599951.001).

[ISSN] 0305-1846

[Journal-full-title] Neuropathology and applied neurobiology

[ISO-abbreviation] Neuropathol. Appl. Neurobiol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Only a few Methyl-[11C]-L-methionine (MET) positron emission tomography (PET) studies have focused on children and young adults with brain neoplasm.

The MET tumor-uptake relative to a corresponding control region was calculated.

A receiver operating characteristic (ROC) was performed to determine the MET-uptake value that best distinguishes tumorous from non-tumorous brain lesions.

A differentiation between high grade malignant lesions (mean MET-uptake = 2.00 +/- 0.46) and low grade tumors (mean MET-uptake = 1.84 +/- 0.31) was not possible.

There was a significant difference in MET-uptake between the histologically homogeneous subgroups of astrocytoma WHO grade II and anaplastic astrocytoma WHO grade III (P = 0.02).

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. (L)-Methionine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Acta Radiol. 1987 Nov-Dec;28(6):673-81 [2962599.001]

[Cites] J Comput Assist Tomogr. 1983 Dec;7(6):1062-6 [6415134.001]

[Cites] Pediatr Neurol. 1990 May-Jun;6(3):163-70 [2193641.001]

[Cites] J Comput Assist Tomogr. 1992 Sep-Oct;16(5):804-13 [1522276.001]

[Cites] J Comput Assist Tomogr. 1994 Jan-Feb;18(1):110-8 [8282858.001]

[Cites] Clin Neurol Neurosurg. 1995 Nov;97(4):349-53 [8599907.001]

[Cites] J Nucl Med. 1996 Feb;37(2):387-93 [8667081.001]

[Cites] Neurology. 1998 May;50(5):1316-22 [9595980.001]

[Cites] Clin Cancer Res. 2004 Nov 1;10(21):7163-70 [15534088.001]

[Cites] J Neurosurg. 2006 Feb;104(2):238-53 [16509498.001]

[Cites] Eur J Nucl Med Mol Imaging. 2006 May;33(5):516-24 [16450140.001]

[Cites] Childs Nerv Syst. 2007 Jul;23(7):739-51 [17356889.001]

[Cites] Neurosurg Rev. 1999 Dec;22(4):210-4 [10682929.001]

[Cites] J Nucl Med. 2000 Jul;41(7):1250-5 [10914918.001]

[Cites] J Nucl Med. 2001 Mar;42(3):432-45 [11337520.001]

[Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):176-82 [11926379.001]

[Cites] Cancer. 2002 Sep 15;95(6):1376-86 [12216107.001]

[Cites] Pediatr Neurosurg. 2003 Mar;38(3):146-55 [12601239.001]

[Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]

[Cites] J Neuroimaging. 2003 Jul;13(3):269-71 [12889176.001]

[Cites] Mol Imaging. 2002 Oct;1(4):309-35 [12926228.001]

[Cites] Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1389-97 [12920486.001]

[Cites] J Neuroimaging. 2004 Oct;14(4):372-6 [15358961.001]

[Cites] Int J Appl Radiat Isot. 1979 Jul;30(7):393-9 [478664.001]

[Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]

(PMID = 19575148.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine; BN630929UL / methionine methyl ester

[Other-IDs] NLM/ PMC2808525

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences.

PURPOSE: To characterize the non-Gaussian diffusion patterns of cerebral glioma microstructure with respect to the different glioma grades by using a new method called diffusional kurtosis (DK) imaging.

A Mann-Whitney test was used to compare each histologic glioma subtype regarding the diffusion measurements.

Receiver operating characteristic curves were used to test for the parameter with the best sensitivity and specificity for glioma grade discrimination.

RESULTS: In 34 patients with cerebral gliomas (five World Health Organization [WHO] grade II astrocytomas, 13 WHO grade III astrocytomas, and 16 WHO grade IV glioblastomas multiforme), significantly different diffusion patterns were found among the three glioma groups.

MK values increased with higher glioma malignancy, whereas ADCs tended to decrease with higher malignancy; FA values did not differ significantly among tumor groups.

Significant differences between astrocytoma grades WHO II and WHO III were demonstrated only by DK values.

Area under the receiver operating characteristic curve was highest for normalized MK (0.972) during testing to discriminate between low- and high-grade gliomas.

CONCLUSION: This study demonstrates specific diffusion patterns for low- and high-grade gliomas, showing that DK imaging is able to depict microstructural changes within glioma tissue and is able to help differentiate among glioma grades. (c) RSNA, 2010.

[MeSH-major] Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Glioma / diagnosis

MedlinePlus Health Information. consumer health - Brain Tumors.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20089718.001).

[ISSN] 1527-1315

[Journal-full-title] Radiology

[ISO-abbreviation] Radiology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Brainstem glioma presenting as pruritus in children with neurofibromatosis-1.

The most common intracranial tumors are low-grade astrocytomas, which most frequently involve the optic pathway, and less often, the brainstem.

In cases of brainstem glioma in NF1, treatment decisions are frequently complicated by the paucity of symptoms referable to the tumor.

Here, we describe 2 children with NF1 whose initial presentation of a growing brainstem glioma was localized pruritus.

[MeSH-major] Brain Stem Neoplasms / diagnosis. Glioma / diagnosis. Neurofibromatosis 1 / diagnosis. Pruritus / diagnosis

Genetic Alliance. consumer health - Glioma.

Genetic Alliance. consumer health - Neurofibromatosis.

MedlinePlus Health Information. consumer health - Itching.

COS Scholar Universe. author profiles.

Xenbase. Xenbase .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19935099.001).

[ISSN] 1536-3678

[Journal-full-title] Journal of pediatric hematology/oncology

[ISO-abbreviation] J. Pediatr. Hematol. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primitive neuroectodermal tumour arising within low grade astrocytoma: transformation, de novo or radiation induced? Report of three cases and review of literature.

The transformation from low grade to aggressive astrocytoma is well known.

However, the development of a completely different tumour such as a primitive neuroectodermal tumour (PNET) within a low grade astrocytoma (LGA) is rare.

All three patients had histologically proven low-grade astrocytoma and received radiotherapy following biopsy.

Two patients underwent partial resection for recurrence, one at five and the other ten years later with histological confirmation of low-grade astrocytoma.

Histology now revealed high grade PNET.

Among the six reported cases of PNET arising following prophylactic radiation therapy to low grade astrocytomas, only two occurred within the original tumour.

Whether these cases represent transformation of low-grade astrocytoma, de novo formation of new tumour or radiation induced neoplasm is uncertain.

[MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Neuroectodermal Tumors, Primitive / etiology

[MeSH-minor] Adolescent. Adult. Fatal Outcome. Female. Humans. Male. Neoplasm Recurrence, Local / etiology

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18568729.001).

[ISSN] 0268-8697

[Journal-full-title] British journal of neurosurgery

[ISO-abbreviation] Br J Neurosurg

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] England

[Number-of-references] 14

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas.

Glioblastomas (GBM) are the most prevalent type of malignant primary brain tumor in adults.

They may manifest de novo or develop from low-grade astrocytomas (LGA) or anaplastic astrocytomas.

Tumor progression is facilitated by an increased activity of proteolytic enzymes such as matrix metalloproteinases (MMPs).

Therefore, MMP-1, MMP-11 and MMP-19 might be of importance for the development of high-grade astrocytic tumors and may be promising targets for therapy.

[MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / enzymology. Glioma / diagnosis. Glioma / enzymology. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 11 / metabolism. Matrix Metalloproteinases, Secreted / metabolism

[MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Disease Progression. Female. Gene Expression Regulation, Enzymologic / genetics. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Matrix Metalloproteinase 9 / genetics. Middle Aged. Neoplasm Invasiveness / genetics. Predictive Value of Tests. Prognosis. RNA, Messenger / analysis. RNA, Messenger / metabolism. World Health Organization

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17980449.001).

[ISSN] 0168-0102

[Journal-full-title] Neuroscience research

[ISO-abbreviation] Neurosci. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Ireland

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinase 11; EC 3.4.24.- / Matrix Metalloproteinases, Secreted; EC 3.4.24.- / matrix metalloproteinase 19; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation.

PURPOSE: To assess the effectiveness of re-irradiation in recurrent low-grade gliomas (LGG).

PATIENTS AND METHODS: Sixty-three patients were treated with fractionated stereotactic re-irradiation in the case of recurrent gliomas.

At primary diagnosis of the tumor, the histology was grade II astrocytoma, oligodendroglioma or oligoastrocytoma.

CONCLUSION: Our retrospective data suggest that stereotactically guided fractionated re-irradiation in recurrent glioma represents an effective treatment option with good results and few complications.

[MeSH-major] Brain Neoplasms / radiotherapy. Dose Fractionation. Glioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy / methods

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Radiation Therapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):996-1003 [14575830.001]

[Cites] Cancer. 1993 Jul 1;72 (1):190-5 [8508405.001]

[Cites] Eur J Cancer. 1998 Jan;34(1):98-102 [9624245.001]

[Cites] Cancer. 1994 Sep 15;74(6):1784-91 [8082081.001]

[Cites] Semin Radiat Oncol. 2001 Apr;11(2):145-51 [11285552.001]

[Cites] Arch Neurol. 1989 Nov;46(11):1238-9 [2818260.001]

[Cites] Arch Neurol. 1990 Oct;47(10):1138-40 [2222248.001]

[Cites] Cancer. 1985 Mar 1;55(5):919-27 [3967199.001]

[Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]

[Cites] Br J Cancer. 2003 Jul 21;89(2):232-8 [12865907.001]

[Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]

[Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]

[Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]

[Cites] Semin Oncol. 1994 Apr;21(2):236-48 [8153667.001]

[Cites] Can J Surg. 1993 Jun;36(3):271-5 [8391917.001]

[Cites] Radiother Oncol. 2000 Nov;57(2):215-23 [11054526.001]

[Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]

[Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8 [9069312.001]

[Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]

[Cites] Neurology. 2000 Apr 11;54(7):1402-3 [10751245.001]

[Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]

[Cites] Radiologe. 1995 Sep;35(9):583-6 [8588040.001]

[Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]

[Cites] J Neurosurg. 1984 Oct;61(4):665-73 [6470776.001]

[Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]

[Cites] Neurosurgery. 1987 Nov;21(5):615-21 [2827052.001]

[Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]

[Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]

[Cites] Cancer. 1997 Jan 15;79(2):370-9 [9010111.001]

[Cites] Oncology. 2000 Feb;58(2):108-16 [10705237.001]

[Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):977-82 [10192343.001]

[Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]

[Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]

[Cites] Semin Surg Oncol. 2001 Jan-Feb;20(1):13-23 [11291128.001]

[Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]

[Cites] J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):291-6 [8795601.001]

[Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]

[Cites] Clin Neurosurg. 1995;42:488-94 [8846613.001]

[Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]

[Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]

[Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]

[Cites] Radiology. 1996 Oct;201(1):275-8 [8816559.001]

[Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]

(PMID = 15735924.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma.

Reduction in the mRNA and protein expression of lipocalin-like prostaglandin D(2) (PGD(2)) synthase (PGDS), the main arachidonic acid metabolite produced in neurons and glial cells of the central nervous system, is a significant biological event involved in the malignant progression of astrocytomas and is predictive of poor survival.

This finding has exciting implications for early interventional efforts for the grade 2 and 3 astrocytomas.

[MeSH-major] Astrocytoma / enzymology. Astrocytoma / pathology. Intramolecular Oxidoreductases / deficiency

[MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Cyclooxygenase 2 / metabolism. Cyclooxygenase Inhibitors / pharmacology. DNA Methylation / drug effects. Drug Screening Assays, Antitumor. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunohistochemistry. Introns / genetics. Lipocalins / genetics. Multivariate Analysis. Proportional Hazards Models. Prostaglandin D2 / pharmacology. Protein Transport / drug effects. Survival Analysis

Genetic Alliance. consumer health - Anaplastic Astrocytoma.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

SciCrunch. ArrayExpress: Data: Microarray .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18852145.001).

[ISSN] 1535-7163

[Journal-full-title] Molecular cancer therapeutics

[ISO-abbreviation] Mol. Cancer Ther.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Lipocalins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.2 / prostaglandin R2 D-isomerase; RXY07S6CZ2 / Prostaglandin D2

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.

Only limited data are available on the role of chemotherapy in low-grade OD.

The authors retrospectively studied the outcome of the procarbazine, lomustine, and vincristine (PCV) chemotherapy regimen in a group of 16 patients with newly diagnosed OD and 5 patients with recurrent low-grade OD.

In the newly diagnosed and responding patients, radiotherapy was withheld until the time of disease recurrence.

The median time to disease progression in this group was >24 months.

Only one of these patients experienced disease progression while receiving chemotherapy.

Several patients showed a signficant clinical improvement despite only a modest improvement of the tumor on the MRI scans.

MRI scans were of limited value for the assessment of response.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

[MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lomustine / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction. Procarbazine / therapeutic use. Retrospective Studies. Tumor Suppressor Protein p53 / genetics. Vincristine / therapeutic use

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. LOMUSTINE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. PROCARBAZINE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2005 American Cancer Society.

(PMID = 15637687.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Complex partial seizures secondary to a low-grade lipoastrocytoma].

[Transliterated title] Crisis parciales complejas secundarias a un lipoastrocitoma de bajo grado.

[MeSH-major] Astrocytoma / complications. Epilepsy, Complex Partial / etiology. Epilepsy, Temporal Lobe / etiology. Lipoma / complications. Supratentorial Neoplasms / complications. Temporal Lobe / pathology

Genetic Alliance. consumer health - Seizures.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18075993.001).

[ISSN] 0210-0010

[Journal-full-title] Revista de neurologia

[ISO-abbreviation] Rev Neurol

[Language] spa

[Publication-type] Case Reports; Letter

[Publication-country] Spain

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?

We investigated the expression of APM components in astrocytomas without detectable defects in HLA class I antigen expression and correlated it with grade of malignancy.

Quantitative immunohistochemical analysis of astrocytomas revealed reduced expression of the cytosolic proteasome subunit low molecular weight protein 2 (LMP2), the endoplasmatic reticulum (ER) transporter associated with antigen processing-1 (TAP1), and the ER chaperone beta2-microglobulin (beta2m) in astrocytoma cells when compared to astrocytes from nonpathological brain.

Among human WHO grade II-IV astrocytomas, downregulation of LMP2, TAP1 and beta2m correlated with grade of malignancy.

Furthermore, astrocytoma cell lines (n = 12) expressed all APM components analyzed at levels comparable to dendritic cells (DC), which were used for comparative purposes.

However, upregulation of beta2m after stimulation with inflammatory cytokines was significantly lower in astrocytoma cell lines than in control cells.

Our results support the hypothesis that coordinated downregulation or impaired upregulation of certain HLA class I APM components may serve as a mechanism for astrocytoma cells to evade the host's immune response, even if HLA class I antigen surface expression is not altered.

[MeSH-major] Antigen Presentation / immunology. Astrocytoma / immunology. Brain Neoplasms / immunology. Histocompatibility Antigens Class I / metabolism. Tumor Escape / immunology

[MeSH-minor] ATP-Binding Cassette Sub-Family B Member 2. ATP-Binding Cassette Transporters / biosynthesis. Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Child. Child, Preschool. Cysteine Endopeptidases / biosynthesis. Down-Regulation. Female. Flow Cytometry. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. World Health Organization. beta 2-Microglobulin / biosynthesis

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17541610.001).

[ISSN] 0001-6322

[Journal-full-title] Acta neuropathologica

[ISO-abbreviation] Acta Neuropathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / ATP-Binding Cassette Sub-Family B Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Histocompatibility Antigens Class I; 0 / TAP1 protein, human; 0 / beta 2-Microglobulin; 144416-78-4 / LMP-2 protein; EC 3.4.22.- / Cysteine Endopeptidases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] PIK3CA alterations in primary (de novo) and secondary glioblastomas.

We assessed alterations in the EGFR/PTEN/PI3K pathway in 107 primary (de novo) glioblastomas and 32 secondary glioblastomas that progressed from low-grade or anaplastic astrocytomas.

Furthermore, this signaling pathway was altered by either PTEN mutations or PIK3CA amplification in 10 of 12 (83%) malignant glioma cell lines analyzed.

[MeSH-major] Gene Expression Regulation, Neoplastic / physiology. Glioblastoma / classification. Glioblastoma / metabolism. Phosphatidylinositol 3-Kinases / metabolism

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17235514.001).

[ISSN] 0001-6322

[Journal-full-title] Acta neuropathologica

[ISO-abbreviation] Acta Neuropathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

The molecular pathogenesis of pediatric astrocytomas is still poorly understood.

To further understand the genetic abnormalities associated with these tumors, we performed a genome-wide analysis of DNA copy number aberrations in pediatric low-grade astrocytomas by using array-based comparative genomic hybridization.

Similarly, a marked proportion of low-grade astrocytomas from adult patients also had BRAF duplication.

Both the stable silencing of BRAF through shRNA lentiviral transduction and pharmacological inhibition of MEK1/2, the immediate downstream phosphorylation target of BRAF, blocked the proliferation and arrested the growth of cultured tumor cells derived from low-grade gliomas.

Our findings implicate aberrant activation of the MAPK pathway due to gene duplication or mutation of BRAF as a molecular mechanism of pathogenesis in low-grade astrocytomas and suggest inhibition of the MAPK pathway as a potential treatment.

[MeSH-major] Astrocytoma / enzymology. Astrocytoma / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Gene Duplication. MAP Kinase Signaling System / physiology. Mitogen-Activated Protein Kinases / metabolism. Proto-Oncogene Proteins B-raf / metabolism

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

SciCrunch. OMIM: Data: Gene Annotation .

SciCrunch. ArrayExpress: Data: Microarray .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Cell Biol. 2002 Oct;22(20):7226-41 [12242299.001]

[Cites] Nat Genet. 2006 Mar;38(3):294-6 [16474404.001]

[Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):896-902 [12387455.001]

[Cites] Cancer Res. 2002 Dec 1;62(23):6997-7000 [12460918.001]

[Cites] Cancer Res. 2003 Mar 15;63(6):1179-82 [12649172.001]

[Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]

[Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]

[Cites] J Biol Chem. 2003 Jul 18;278(29):26958-69 [12730209.001]

[Cites] Br J Cancer. 2000 Mar;82(6):1218-22 [10735509.001]

[Cites] J Biol Chem. 2000 Oct 13;275(41):31876-82 [10884385.001]

[Cites] Histopathology. 2000 Nov;37(5):437-44 [11119125.001]

[Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):279-84 [11807985.001]

[Cites] Med Pediatr Oncol. 2002 Mar;38(3):173-7 [11836716.001]

[Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]

[Cites] Nature. 2002 Aug 29;418(6901):934 [12198537.001]

[Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]

[Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]

[Cites] Nature. 1987 May 28-Jun 3;327(6120):293-7 [3587348.001]

[Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]

[Cites] Hum Genet. 1988 Nov;80(3):224-34 [3192212.001]

[Cites] Cancer Genet Cytogenet. 1989 Jun;39(2):253-79 [2752377.001]

[Cites] Genomics. 1991 Mar;9(3):517-23 [1840567.001]

[Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]

[Cites] Cancer Genet Cytogenet. 1997 Sep;97(2):125-34 [9283596.001]

[Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):399-407 [9408757.001]

[Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):157-60 [9666811.001]

[Cites] Clin Cancer Res. 1997 Apr;3(4):523-30 [9815715.001]

[Cites] Cancer Res. 1999 Feb 15;59(4):803-6 [10029066.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11335-40 [10500177.001]

[Cites] Acta Neuropathol. 2004 Dec;108(6):467-70 [15517309.001]

[Cites] Cancer Res. 2004 Dec 15;64(24):8816-20 [15604238.001]

[Cites] J Clin Invest. 2005 Jan;115(1):94-101 [15630448.001]

[Cites] Science. 2006 Mar 3;311(5765):1287-90 [16439621.001]

[Cites] Nat Med. 2006 Mar;12(3):283-5 [16520774.001]

[Cites] Cell. 2006 Mar 24;124(6):1283-98 [16564017.001]

[Cites] J Neuropathol Exp Neurol. 2006 Aug;65(8):794-807 [16896313.001]

[Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]

[Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]

[Cites] Oncogene. 2007 Feb 15;26(7):1088-97 [16909113.001]

[Cites] J Clin Oncol. 2007 Feb 20;25(6):682-9 [17308273.001]

[Cites] J Mol Med (Berl). 2007 Mar;85(3):227-35 [17211612.001]

[Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]

[Cites] Cancer Res. 2007 Apr 15;67(8):3551-4 [17440063.001]

[Cites] J Invest Dermatol. 2007 Jun;127(6):1468-70 [17301836.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):121-33 [17588166.001]

[Cites] Nat Genet. 2007 Aug;39(8):1013-7 [17603482.001]

[Cites] Nat Genet. 2007 Aug;39(8):1007-12 [17603483.001]

[Cites] Neuropediatrics. 2007 Apr;38(2):61-3 [17712732.001]

[Cites] Brain Pathol. 2008 Jul;18(3):326-37 [18371186.001]

[Cites] Acta Neuropathol. 2005 Feb;109(2):207-10 [15791479.001]

[Cites] Genes Chromosomes Cancer. 2005 Jul;43(3):294-301 [15834944.001]

[Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]

[Cites] Neurology. 2005 Oct 25;65(8):1335-6 [16247081.001]

[Cites] J Clin Oncol. 2005 Dec 1;23(34):8853-62 [16314645.001]

[Cites] J Biol Chem. 2006 Feb 17;281(7):3800-9 [16316983.001]

[Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]

(PMID = 18398503.001).

[ISSN] 0021-9738

[Journal-full-title] The Journal of clinical investigation

[ISO-abbreviation] J. Clin. Invest.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Cyclin D; 0 / Cyclins; 0 / Enzyme Inhibitors; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.24 / Mitogen-Activated Protein Kinases

[Other-IDs] NLM/ PMC2289793

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HSV encephalitis in a child with brain stem glioma: a rare complication of therapy. Case report and review of the neurosurgical literature.

CASE REPORT: A 13-year-old boy was diagnosed with an inoperable, biopsy-proven pontine grade II astrocytoma.

He made slow improvement but died 8 months after diagnosis from tumor progression.

A low threshold for both investigation with CSF PCR and empirical treatment with intravenous aciclovir is warranted.

[MeSH-major] Astrocytoma / complications. Brain Stem Neoplasms / complications. Encephalitis, Herpes Simplex / etiology. Herpesvirus 1, Human. Radiotherapy / adverse effects

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Radiation Therapy.

The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for brain stem glioma .

Hazardous Substances Data Bank. ACYCLOVIR .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Neurosurg. 1972 Apr;36(4):499-502 [4335254.001]

[Cites] Hum Pathol. 1998 Mar;29(3):215-22 [9496822.001]

[Cites] Childs Nerv Syst. 1997 Jun;13(6):352-5 [9272290.001]

[Cites] Clin Infect Dis. 2003 May 15;36(10):1335-9 [12746782.001]

[Cites] J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):239-42 [10407001.001]

[Cites] Herpes. 2004 Jun;11 Suppl 2:48A-56A [15319090.001]

[Cites] J Clin Microbiol. 1998 Aug;36(8):2229-34 [9665997.001]

[Cites] Antiviral Res. 2006 Sep;71(2-3):141-8 [16675036.001]

[Cites] J Virol. 1999 Dec;73(12):10514-8 [10559370.001]

[Cites] Neuroradiology. 1996 Jan;38(1):73-9 [8773284.001]

[Cites] Pediatr Neurol. 2003 Jul;29(1):69-71 [13679127.001]

[Cites] N Engl J Med. 1986 Jan 16;314(3):144-9 [3001520.001]

[Cites] Neurosurgery. 1999 Mar;44(3):633-5; discussion 635-6 [10069600.001]

[Cites] Herpes. 2004 Jun;11 Suppl 2:57A-64A [15319091.001]

(PMID = 17593375.001).

[ISSN] 0256-7040

[Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

[ISO-abbreviation] Childs Nerv Syst

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Germany

[Chemical-registry-number] 0 / Antiviral Agents; X4HES1O11F / Acyclovir

[Number-of-references] 14

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.

A total of 221 somatic IDH1 mutations were detected and the highest frequencies occurred in diffuse astrocytomas (68%), oligodendrogliomas (69%), oligoastrocytomas (78%) and secondary glioblastomas (88%).

Primary glioblastomas and other entities were characterized by a low frequency or absence of mutations in amino acid position 132 of IDH1.

The very high frequency of IDH1 mutations in WHO grade II astrocytic and oligodendroglial gliomas suggests a role in early tumor development.

[MeSH-minor] Astrocytoma / genetics. Astrocytoma / pathology. Base Sequence. DNA Mutational Analysis. Disease Progression. Gene Frequency. Glioblastoma / genetics. Glioblastoma / pathology. Glioma / etiology. Glioma / pathology. Humans. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Polymerase Chain Reaction

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18985363.001).

[ISSN] 1432-0533

[Journal-full-title] Acta neuropathologica

[ISO-abbreviation] Acta Neuropathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC.

Although the oncogenic and tumor suppressive functions of several miRNAs have been characterized, the role of miRNAs in mediating tumor invasion and migration remains largely unexplored.

Here, we performed real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays on 43 glioma samples (17 glioblastoma, 6 anaplastic astrocytoma, 10 low-grade astrocytoma, 6 oligodendroglioma and 4 ependymoma) and 6 glioma cell lines.

We found that miR-10b expression was upregulated in all glioma samples compared to non-neoplastic brain tissues.

The expression levels of miR-10b were associated with higher grade glioma.

Finally, multifocal lesions on enhanced MRI of 7 malignant gliomas were associated with higher expression levels of miR-10b (p = 0.02).

Our data indicated that miR-10b might play some role in the invasion of glioma cells.

[MeSH-major] Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic / physiology. Glioma / genetics. Membrane Glycoproteins / genetics. Receptors, Immunologic / genetics. Receptors, Urokinase Plasminogen Activator / genetics. rho GTP-Binding Proteins / genetics

[MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Up-Regulation

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2009 UICC

(PMID = 19536818.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / LILRB2 protein, human; 0 / Membrane Glycoproteins; 0 / RHOC protein, human; 0 / RNA, Messenger; 0 / Receptors, Immunologic; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.6.5.2 / rho GTP-Binding Proteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

DWI studies were performed together with T1-weighted postcontrast magnetic resonance imaging (MRI) in four patients with lesions in or adjacent to the OR (glioblastoma, oligo-astrocytoma, cavernoma, and metastasis; n = 1 each).

Preoperative and postoperative neuroophthalmological testing included, among others, perimetry to define the value of diffusion-weighted image guidance during OR lesion resection.

In one case, low-grade tumor parts infiltrating the OR were intentionally left.

[MeSH-major] Affect / physiology. Deep Brain Stimulation. Parkinson Disease / psychology. Parkinson Disease / therapy. Subthalamic Nucleus / physiology

MedlinePlus Health Information. consumer health - Parkinson's Disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Radiology. 1996 Dec;201(3):637-48 [8939209.001]

[Cites] J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):501-3 [10727488.001]

[Cites] AJNR Am J Neuroradiol. 1996 Aug;17(7):1379-83 [8871728.001]

[Cites] Microsc Res Tech. 2000 Dec 1;51(5):481-92 [11074619.001]

[Cites] Neurosurgery. 2001 Jul;49(1):86-92; discussion 92-3 [11440464.001]

[Cites] Neurosurgery. 2000 Aug;47(2):417-26; discussion 426-7 [10942015.001]

[Cites] Clin Neurosurg. 2002;49:90-102 [12506550.001]

[Cites] Acta Ophthalmol (Copenh). 1976 Dec;54(6):827-41 [990032.001]

[Cites] Epilepsia. 1999 Aug;40(8):1155-8 [10448831.001]

[Cites] Acta Neurochir (Wien). 1988;92(1-4):29-36 [3407471.001]

[Cites] Neuroimage. 1999 Mar;9(3):352-61 [10075905.001]

[Cites] J Neurosurg. 1999 Apr;90(4):791-5 [10193629.001]

[Cites] Acta Neurochir (Wien). 2004 Mar;146(3):265-9; discussion 269-70 [15015049.001]

[Cites] Surg Neurol. 2003 Nov;60(5):381-90; discussion 390 [14572954.001]

[Cites] Neuroimage. 1999 Nov;10(5):489-99 [10547327.001]

[Cites] Neurosurgery. 2000 Nov;47(5):1070-9; discussion 1079-80 [11063099.001]

[Cites] Neurol Clin. 2003 May;21(2):417-43, vi [12916486.001]

[Cites] Neuroimage. 2003 Oct;20(2):1140-53 [14568483.001]

[Cites] Ann Neurol. 1997 Dec;42(6):951-62 [9403488.001]

[Cites] Surg Neurol. 2002 Nov;58(5):302-7; discussion 308 [12504288.001]

(PMID = 15747136.001).

[ISSN] 0344-5607

[Journal-full-title] Neurosurgical review

[ISO-abbreviation] Neurosurg Rev

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Frequent loss of heterozygosity and altered expression of the candidate tumor suppressor gene 'FAT' in human astrocytic tumors.

BACKGROUND: We had earlier used the comparison of RAPD (Random Amplification of Polymorphic DNA) DNA fingerprinting profiles of tumor and corresponding normal DNA to identify genetic alterations in primary human glial tumors.

METHODS: In this study we used RAPD-PCR to identify novel genomic alterations in the astrocytic tumors of WHO grade II (Low Grade Diffuse Astrocytoma) and WHO Grade IV (Glioblastoma Multiforme).

RESULTS: Bands consistently altered in the RAPD profile of tumor DNA in a significant proportion of tumors were identified.

One such 500 bp band, that was absent in the RAPD profile of 33% (4/12) of the grade II astrocytic tumors, was selected for further study.

Its sequence corresponded with a region of FAT, a putative tumor suppressor gene initially identified in Drosophila.

Fifty percent of a set of 40 tumors, both grade II and IV, were shown to have Loss of Heterozygosity (LOH) at this locus by microsatellite (intragenic) and by SNP markers.

Semi-quantitative RT-PCR showed low FAT mRNA levels in a major subset of tumors.

CONCLUSION: These results point to a role of the FAT in astrocytic tumorigenesis and demonstrate the use of RAPD analysis in identifying specific alterations in astrocytic tumors.

[MeSH-major] Astrocytoma / genetics. Cadherins / genetics. Central Nervous System Neoplasms / genetics. Genes, Tumor Suppressor. Loss of Heterozygosity

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Dev Dyn. 2000 Mar;217(3):233-40 [10741417.001]

[Cites] J Neurooncol. 2000 May;48(1):1-12 [11026691.001]

[Cites] Cancer Genet Cytogenet. 2001 Feb;125(1):41-5 [11297766.001]

[Cites] Mutat Res. 2001 Dec 12;484(1-2):53-9 [11733071.001]

[Cites] Yonsei Med J. 2002 Apr;43(2):145-51 [11971207.001]

[Cites] Int J Cancer. 2002 May 10;99(2):193-200 [11979433.001]

[Cites] Cancer Lett. 2002 Aug 28;182(2):193-202 [12048165.001]

[Cites] Chin Med J (Engl). 2002 Aug;115(8):1201-4 [12215292.001]

[Cites] Histol Histopathol. 2003 Jan;18(1):207-16 [12507300.001]

[Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):93-8 [14603447.001]

[Cites] EMBO J. 2004 Oct 1;23(19):3769-79 [15343270.001]

[Cites] Dev Biol. 1988 Oct;129(2):541-54 [3417051.001]

[Cites] Nucleic Acids Res. 1990 Nov 25;18(22):6531-5 [1979162.001]

[Cites] Cancer Surv. 1990;9(4):631-44 [1983210.001]

[Cites] Biotechniques. 1993 Sep;15(3):388-90 [8105827.001]

[Cites] Brain Pathol. 1993 Jan;3(1):19-26 [8269081.001]

[Cites] Trends Genet. 1995 Jun;11(6):242-6 [7543710.001]

[Cites] Biotechniques. 1995 Jul;19(1):38, 40-2 [7669294.001]

[Cites] Genomics. 1995 Nov 20;30(2):207-23 [8586420.001]

[Cites] Indian J Biochem Biophys. 1996 Dec;33(6):455-7 [9219429.001]

[Cites] Gene. 1998 Jan 5;206(1):45-8 [9461413.001]

[Cites] Mech Dev. 1999 Feb;80(2):207-12 [10072790.001]

[Cites] Arch Neurol. 1999 Apr;56(4):439-41 [10199332.001]

[Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]

[Cites] Gene Expr Patterns. 2005 Apr;5(4):483-90 [15749076.001]

[Cites] Cancer. 2005 May 15;103(10):2132-42 [15830341.001]

[Cites] Genes Chromosomes Cancer. 2005 Jul;43(3):260-72 [15838843.001]

[Cites] World J Gastroenterol. 2005 May 28;11(20):3034-9 [15918185.001]

[Cites] J Cell Sci. 2005 Jun 1;118(Pt 11):2347-53 [15923647.001]

[Cites] World J Gastroenterol. 2005 Jul 14;11(26):4102-7 [15996039.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2220-3 [16172235.001]

[Cites] Int J Cancer. 2005 Nov 20;117(4):683-9 [15912534.001]

[Cites] Clin Chem. 2006 Mar;52(3):370-8 [16397012.001]

[Cites] Nat Genet. 2006 Oct;38(10):1142-50 [16980976.001]

[Cites] Curr Biol. 2006 Nov 7;16(21):2101-10 [17045801.001]

[Cites] Eur J Med Genet. 2007 Jan-Feb;50(1):66-72 [17081814.001]

[Cites] J Neurooncol. 2007 Feb;81(3):249-55 [17019533.001]

[Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]

[Cites] Oncogene. 2007 Aug 9;26(36):5300-8 [17325662.001]

[Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]

[Cites] Genes Dev. 2007 Nov 1;21(21):2747-61 [17974916.001]

[Cites] BMC Cancer. 2007;7:190 [17925012.001]

[Cites] J Biol Chem. 2008 Feb 29;283(9):5496-509 [18158288.001]

[Cites] Cancer Res. 2008 Apr 15;68(8):2789-94 [18413746.001]

(PMID = 19126244.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Cadherins; 0 / DNA Primers; 0 / FAT1 protein, human

[Other-IDs] NLM/ PMC2631005

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.

The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) is a key player in tumor cell resistance.

However, it is unclear whether MGMT promoter methylation correlates with MGMT activity and whether MGMT promoter methylation of the pretreatment tumor predicts the MGMT status of recurrences.

To address these questions, we determined MGMT activity promoter methylation and immunoreactivity in pretreatment and recurrent glioblastomas (GB, WHO Grade IV), and in astrocytomas (WHO Grade III).

For astrocytomas, promoter-methylated samples displayed 0-28 fmol/mg and, nonmethylated samples, 23-107 fmol/mg.

Given a threshold level of 30 fmol/mg of protein, we found a correlation between promoter methylation and no/low MGMT activity in 82.4% of the tumors.

Therefore, classification of hemimethylated tumors remains questionable.

Although individual exceptions were found, the data show an overall correlation between promoter methylation and lack/low MGMT activity in GB and astrocytomas.

[MeSH-major] Astrocytoma / enzymology. Astrocytoma / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. Glioblastoma / enzymology. Glioblastoma / genetics. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

[MeSH-minor] Cell Line, Tumor. Humans. Immunohistochemistry. Recurrence

Genetic Alliance. consumer health - Glioblastoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20131314.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.

YKL-40 is a secreted chitinase-like molecule whose expression is associated with glioma grade.

Expression is higher in astrocytomas than oligodendrogliomas and has been reported to predict shorter survival and radiation resistance in glioblastomas (GBMs).

Whether YKL-40 is directly produced by glioma cells or other admixed nonneo-plastic cells, and whether it correlates with 1p/19q status or other hallmark molecular abnormalities, are unclear.

A rank-order list of YKL-40 expression was determined immunohistochemically in 79 untreated high-grade adult glio-mas, including 28 anaplastic oligodendrogliomas (AOs) and 51 GBMs.

Relative YKL-40 expression was compared with glioma class, key molecular alterations, and immunohistochemical markers via a series of Spearman rank correlations.

YKL-40 mRNA was abundant in glioma cells as well as reactive astrocytes, but was low in admixed neurons and macrophages.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]

[Cites] Oncogene. 2009 Dec 17;28(50):4456-68 [19767768.001]

[Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]

[Cites] Biochem J. 2002 Jul 1;365(Pt 1):119-26 [12071845.001]

[Cites] Cancer. 2002 Jul 15;95(2):267-74 [12124825.001]

[Cites] Cancer Res. 2002 Aug 1;62(15):4364-8 [12154041.001]

[Cites] Int J Cancer. 2002 Oct 10;101(5):454-60 [12216074.001]

[Cites] J Neurosurg. 2002 Dec;97(6):1397-401 [12507139.001]

[Cites] Clin Cancer Res. 2003 Oct 1;9(12):4423-34 [14555515.001]

[Cites] Biochem J. 2004 Jun 15;380(Pt 3):651-9 [15015934.001]

[Cites] Cancer Res. 1997 Jan 15;57(2):304-9 [9000573.001]

[Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]

[Cites] Cancer Sci. 2005 Mar;96(3):183-90 [15771622.001]

[Cites] Clin Cancer Res. 2005 Mar 15;11(6):2258-64 [15788675.001]

[Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]

[Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]

[Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8644-52 [16361549.001]

[Cites] Neurosurg Focus. 2005 Nov;19(5):E2 [16398466.001]

[Cites] Cancer. 2006 Mar 1;106(5):1130-9 [16456816.001]

[Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]

[Cites] J Biol Chem. 2006 Oct 6;281(40):29583-96 [16882657.001]

[Cites] J Neuropathol Exp Neurol. 2006 Dec;65(12):1149-56 [17146289.001]

[Cites] Gynecol Oncol. 2007 Feb;104(2):435-42 [17023034.001]

[Cites] World J Surg Oncol. 2007;5:17 [17286869.001]

[Cites] Clin Cancer Res. 2007 Mar 1;13(5):1429-37 [17332285.001]

[Cites] J Clin Oncol. 2007 Jun 1;25(16):2288-94 [17538175.001]

[Cites] Clin Cancer Res. 2007 Jun 1;13(11):3244-9 [17545529.001]

[Cites] Int J Cancer. 2008 Feb 15;122(4):857-63 [17957792.001]

[Cites] Urol Oncol. 2008 Jan-Feb;26(1):47-52 [18190830.001]

[Cites] Eur J Haematol. 2008 Apr;80(4):310-7 [18182077.001]

[Cites] Int J Cancer. 2008 May 15;122(10):2187-98 [18092325.001]

[Cites] Am J Pathol. 2008 Jul;173(1):130-43 [18556781.001]

[Cites] Adv Ther. 2008 Aug;25(8):801-9 [18670741.001]

[Cites] FEBS Lett. 2008 Sep 22;582(21-22):3193-200 [18708058.001]

[Cites] Oncogene. 2008 Nov 6;27(52):6679-89 [18724390.001]

[Cites] Ann Oncol. 2009 Jan;20(1):71-7 [18723551.001]

[Cites] J Clin Oncol. 2009 Feb 1;27(4):572-8 [19075264.001]

[Cites] BMC Cancer. 2009;9:8 [19134206.001]

[Cites] Brain Pathol. 2009 Jul;19(3):439-48 [18652591.001]

[Cites] Biochem Biophys Res Commun. 2009 Oct 23;388(3):511-6 [19666003.001]

[Cites] Hum Pathol. 2009 Dec;40(12):1790-7 [19765801.001]

[Cites] Clin Cancer Res. 2002 Jan;8(1):196-201 [11801559.001]

(PMID = 20224722.001).

[ISSN] 1936-2625

[Journal-full-title] International journal of clinical and experimental pathology

[ISO-abbreviation] Int J Clin Exp Pathol

[Language] ENG

[Grant] United States / NIMH NIH HHS / MH / K24 MH001717; United States / PHS HHS / / K24 M401717

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Adipokines; 0 / CHI3L1 protein, human; 0 / Glycoproteins; 0 / Lectins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor

[Other-IDs] NLM/ PMC2836500

[Keywords] NOTNLM ; 10q / 1p19q / EGFR / YKL-40 / glioblastoma / oligodendroglioma

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells.

In this study, we examined the expression and functions of related to testes-specific, vespid, and pathogenesis protein 1 (RTVP-1) in glioma cells.

RTVP-1 was expressed in high levels in glioblastomas, whereas its expression in low-grade astrocytomas and normal brains was very low.

Transfection of glioma cells with small interfering RNAs targeting RTVP-1 decreased cell proliferation in all the cell lines examined and induced cell apoptosis in some of them.

Overexpression of RTVP-1 increased astrocyte and glioma cell proliferation and the anchorage-independent growth of the cells.

In addition, overexpression of RTVP-1 rendered glioma cells more resistant to the apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand and serum deprivation.

Finally, we found that RTVP-1 regulated the invasion of glioma cells as was evident by their enhanced migration through Matrigel and by their increased invasion in a spheroid confrontation assay.

Our results suggest that the expression of RTVP-1 is correlated with the degree of malignancy of astrocytic tumors and that RTVP-1 is involved in the regulation of the growth, survival, and invasion of glioma cells.

Collectively, these findings suggest that RTVP-1 is a potential therapeutic target in gliomas.

[MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glioma / metabolism. Glioma / pathology. Neoplasm Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis

[MeSH-minor] Amino Acid Sequence. Apoptosis / physiology. Astrocytoma / enzymology. Astrocytoma / metabolism. Astrocytoma / pathology. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Survival / physiology. Glioblastoma / enzymology. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Matrix Metalloproteinase 2 / metabolism. Molecular Sequence Data. Neoplasm Invasiveness

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16618735.001).

[ISSN] 0008-5472

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA-R21-96965

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / GLIPR1 protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; EC 3.4.24.24 / Matrix Metalloproteinase 2

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Magnetic resonance imaging characteristics of pilomyxoid astrocytoma.

OBJECTIVE: Pilomyxoid astrocytoma (PMA) is a recently identified pediatric low-grade neoplasm that was previously classified as pilocytic astrocytoma (PA), yet demonstrates unique histological features and more aggressive behavior.

These tumors have been shown to have significantly shorter progression-free and overall survival probability than classical low-grade astrocytomas, as well as a high rate of cerebrospinal fluid (CSF) dissemination.

Radiographic characteristics of the tumor were recorded in each case.

CONCLUSION: Pilomyxoid astrocytoma is a well-circumscribed pediatric neoplasm that commonly originates from the midline of the neuroaxis and lacks peritumoral edema or central necrosis.

It is critical to recognize the predominantly solid and well-circumscribed nature of the neoplasm to avoid confusion with an infiltrating astrocytoma.

[MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

MedlinePlus Health Information. consumer health - MRI Scans.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18662499.001).

[ISSN] 0161-6412

[Journal-full-title] Neurological research

[ISO-abbreviation] Neurol. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Functional outcome after low-grade astrocytoma treatment in childhood.

BACKGROUND: The relatively high survival rate of patients with low-grade astrocytoma necessitates increasing attention to physical and psychosocial outcomes.

The objective of the current study was to investigate functional outcomes among children who were treated for low-grade or pilocytic astrocytoma in different areas of the brain.

CONCLUSIONS: At long-term follow-up, children who had low-grade or pilocytic astrocytomas were found to have poor functional outcomes, depending on tumor site, age, and recurrence.

Therefore, the authors suggest a long-term follow-up of children who are treated for low-grade or pilocytic astrocytomas at a young age to detect and subsequently offer support focused on the medical and cognitive impairments as well as on the behavioral and social consequences of their disease.

[MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Disabled Children. Quality of Life

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16353203.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas.

PURPOSE: The prognostic role of extent of resection (EOR) of low-grade gliomas (LGGs) is a major controversy.

Region-of-interest analysis was performed to measure tumor volumes based on fluid-attenuated inversion-recovery (FLAIR) imaging.

RESULTS: Median preoperative and postoperative tumor volumes and EOR were 36.6 cm(3) (range, 0.7 to 246.1 cm(3)), 3.7 cm(3) (range, 0 to 197.8 cm(3)) and 88.0% (range, 5% to 100%), respectively.

After adjusting each measure of tumor burden for age, Karnofsky performance score (KPS), tumor location, and tumor subtype, OS was predicted by EOR (hazard ratio [HR] = 0.972; 95% CI, 0.960 to 0.983; P < .001), log preoperative tumor volume (HR = 4.442; 95% CI, 1.601 to 12.320; P = .004), and postoperative tumor volume (HR = 1.010; 95% CI, 1.001 to 1.019; P = .03), progression-free survival was predicted by log preoperative tumor volume (HR = 2.711; 95% CI, 1.590 to 4.623; P <or= .001) and postoperative tumor volume (HR = 1.007; 95% CI, 1.001 to 1.014; P = .035), and malignant progression-free survival was predicted by EOR (HR = 0.983; 95% CI, 0.972 to 0.995; P = .005) and log preoperative tumor volume (HR = 3.826; 95% CI, 1.632 to 8.969; P = .002).

[MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Oligodendroglioma / surgery

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18323558.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hypertrophic olivary degeneration after resection of a cerebellar tumor.

We report a case of hypertrophic olivary degeneration due to cerebellar surgery for a low-grade tumor.

A 27-year-old female presented with right-sided paresthesias and intermittent leg paresis following a right cerebellar resection of a tumor 2 weeks prior.

An MRI scan revealed a hypertrophied left anterolateral medulla with increased T2 signal and no diffusion abnormality.

Hypertrophic olivary degeneration may be mistaken for tumor progression, post-operative vasculopathy or granulation tissue and should be considered in patients undergoing cerebellar surgery.

[MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery. Neurosurgical Procedures / adverse effects. Olivary Nucleus / pathology

[MeSH-minor] Adult. Ataxia / etiology. Diagnosis, Differential. Female. Humans. Hypertrophy. Hypesthesia / etiology. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / pathology

Genetic Alliance. consumer health - Cerebellar Degeneration.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Arq Neuropsiquiatr. 2003 Jun;61(2B):473-7 [12894288.001]

[Cites] J Neurosurg. 2004 Apr;100(4):717 [15070130.001]

[Cites] Mov Disord. 1997 May;12(3):432-7 [9159743.001]

[Cites] Acta Neuropathol. 1981;54(4):275-82 [7270084.001]

[Cites] Brain. 2002 Jun;125(Pt 6):1348-57 [12023323.001]

[Cites] Clin Imaging. 1999 Jul-Aug;23(4):215-7 [10631896.001]

[Cites] Eur J Paediatr Neurol. 2007 Jul;11(4):232-4 [17400009.001]

[Cites] Neuroradiology. 1993;35(5):335-8 [8327105.001]

[Cites] J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):797-9 [12754356.001]

[Cites] Arq Neuropsiquiatr. 2005 Jun;63(2A):321-3 [16100982.001]

[Cites] Radiology. 1999 Dec;213(3):814-7 [10580959.001]

[Cites] Pediatr Radiol. 1998 Nov;28(11):830-1 [9799311.001]

[Cites] Eur Neurol. 1998;39(2):97-102 [9520070.001]

[Cites] AJNR Am J Neuroradiol. 2000 Jun-Jul;21(6):1073-7 [10871017.001]

[Cites] AJNR Am J Neuroradiol. 1994 Oct;15(9):1715-9 [7847219.001]

[Cites] Neurology. 1991 Apr;41(4):557-62 [2011257.001]

[Cites] Radiology. 1994 Aug;192(2):539-43 [8029428.001]

(PMID = 18217209.001).

[ISSN] 0167-594X

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles.

Although World Health Organization (WHO) grade I pilocytic astrocytomas and grade II diffuse astrocytomas have been classified for decades as different clinicopathologic entities, few, if any, data are available on the biologic features explaining these differences.

Although more than 50 microarray-related studies have been carried out to characterize the molecular profiles of astrocytic tumors, we have identified only 11 that provide sound data on low-grade astrocytomas.

We have incorporated these data into a comparative analysis for the purpose of identifying the most relevant molecular markers characterizing grade I pilocytic and grade II diffuse astrocytomas.

Our analysis has identified various interesting genes that are differentially expressed in either grade I or grade II astrocytomas when compared with normal tissue and/or high-grade (WHO grade III and IV) astrocytomas.

Interestingly, a group of 6 genes (TIMP4, C1NH, CHAD, THBS4, IGFBP2, and TLE2) constitute an expression profile characteristic of grade I astrocytomas as compared with all other categories of tissue (normal brain, grade II, and high-grade astrocytomas).

The end products (proteins) of these genes act as antimigratory compounds, a fact that could explain why pilocytic astrocytomas behave as compact (well-circumscribed) tumors as opposed to all the other astrocytic tumor types that diffusely invade the brain parenchyma.

Having validated these molecular markers by means of real-time reverse transcriptase-polymerase chain reaction, an integrated model was proposed illustrating how and why pilocytic astrocytomas constitute a distinct biologic and pathologic entity when compared with diffuse astrocytomas.

[MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic / genetics. Genetic Predisposition to Disease / genetics

[MeSH-minor] Adult. Cell Adhesion / genetics. Cell Movement / genetics. Child. Extracellular Matrix Proteins / genetics. Extracellular Matrix Proteins / metabolism. Humans. Models, Neurological. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / physiopathology. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16896313.001).

[ISSN] 0022-3069

[Journal-full-title] Journal of neuropathology and experimental neurology

[ISO-abbreviation] J. Neuropathol. Exp. Neurol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?

The aim of the present study was to evaluate whether extended analyses of O-(2-18F-fluoroethyl)-L-tyrosine (FET) uptake kinetics provide results superior to those of standard tumor-to-background ratios in predicting tumor grade in patients with pretreated gliomas.

METHODS: Dynamic 18F-FET PET studies (0-40 min after injection of 180 MBq of 18F-FET) were performed on 45 glioma patients with suspected tumor recurrence after multimodal treatment.

For the standard method, tumoral maximal standardized uptake value (SUVmax) and the ratio to the background were derived from a summed image 20-40 min after injection.

Results were correlated with the histopathologic findings of MRI/PET-guided stereotactic biopsies and were evaluated with respect to their discriminatory power to separate low- from high-grade tumors using receiver-operating characteristic (ROC) analyses.

RESULTS: The parameters taking into account the individual time course of 18F-FET uptake were able to differentiate low-grade from high-grade recurrent astrocytomas with high diagnostic accuracy, reaching the best differentiation with a sensitivity and specificity of 92% and an area under the ROC curve (AUC) of 0.94.

The lowest performance was provided by the standard method (SUVmax: 73% sensitivity, 54% specificity, and 0.60 AUC; SUVmax-to-background ratio: 62% sensitivity, 62% specificity, and 0.59 AUC).

Time-activity curves (5-40 min after injection) slightly and steadily increased in tumor-free patients and in low-grade tumors, whereas high-grade tumors showed an early peak around 10-15 min after injection followed by a decrease.

CONCLUSION: This study has shown differences in the dynamics of 18F-FET uptake between recurrent low- and high-grade gliomas.

[MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / radionuclide imaging. Glioma / metabolism. Glioma / radionuclide imaging. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / radionuclide imaging. Tyrosine / analogs & derivatives

MedlinePlus Health Information. consumer health - Brain Tumors.

Hazardous Substances Data Bank. L-TYROSINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] J Nucl Med. 2006 May;47(5):806

(PMID = 16513607.001).

[ISSN] 0161-5505

[Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine

[ISO-abbreviation] J. Nucl. Med.

[Language] eng

[Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / O-(2-fluoroethyl)tyrosine; 0 / Radiopharmaceuticals; 42HK56048U / Tyrosine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.

Leptomeningeal dissemination of low-grade gliomas is an uncommon event.

A nonenhancing lesion in the right cerebellar peduncle was identified, subtotally resected, and diagnosed as a grade II astrocytoma.

Complete remission was achieved after 12 months of treatment and the patient is still free from the disease after a follow-up of 24 months.

Genetic Alliance. consumer health - Oligoastrocytoma.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. DACARBAZINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]

[Cites] Neuro Oncol. 2002 Oct;4(4):253-60 [12356355.001]

[Cites] Clin Cancer Res. 2004 Jun 1;10 (11):3728-36 [15173079.001]

[Cites] J Neurooncol. 2002 May;57(3):231-9 [12125986.001]

[Cites] Ann Pharmacother. 2000 Oct;34(10):1173-8 [11054987.001]

[Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]

[Cites] Arch Neurol. 1995 Sep;52(9):912-7 [7661730.001]

[Cites] J Clin Oncol. 2005 May 20;23(15):3605-13 [15908671.001]

[Cites] Ann Oncol. 2003 Dec;14 (12 ):1715-21 [14630674.001]

[Cites] Clin Neurol Neurosurg. 2009 May;111(4):390-4 [19128871.001]

[Cites] Acta Neurochir (Wien). 1994;126(2-4):84-92 [8042560.001]

[Cites] Clin Cancer Res. 1999 Nov;5(11):3394-402 [10589750.001]

[Cites] J Neurooncol. 2007 Jul;83(3):303-6 [17245619.001]

[Cites] Cancer. 1994 Jun 1;73(11):2869-78 [8194029.001]

[Cites] Oncologist. 2006 Jun;11(6):681-93 [16794247.001]

(PMID = 19876600.001).

[ISSN] 1573-7373

[Journal-full-title] Journal of neuro-oncology

[ISO-abbreviation] J. Neurooncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 04079A1RDZ / Cytarabine; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In cases of brain tumor, PWI aids in grading and better differentiation in diagnostics as well as for pre-therapeutic planning.

PWI allows better estimates of biological activity and aggressiveness in low grade brain tumors, and in the case of WHO grade II astrocytoma showing anaplasically transformed tumor areas, allows more rapid visu-alization and a better prediction of the course of the disease than conventional MRI diagnostics.

Diffusion imaging can be used for describing brain tumors, for evaluating contralateral involvement and the course of the nerve fibers near the tumor.

Diagnostic problems such as the differentiation between neoplastic and non-neoplastic lesions, grading cerebral glioma and distinguishing between primary brain tumors and metastases can be resolved.

[MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Diffusion Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods

MedlinePlus Health Information. consumer health - Brain Tumors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Radiologe. 2005 Apr;45(4):327-39 [15800783.001]

[Cites] AJNR Am J Neuroradiol. 2000 Oct;21(9):1603-10 [11039338.001]

[Cites] Neuroradiology. 2006 Apr;48 Suppl 1:3-8 [16699847.001]

[Cites] Radiologe. 2004 Jul;44(7):723-32; quiz 733-4 [15241598.001]

[Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]

[Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):478-82 [11567824.001]

[Cites] Radiology. 1994 Dec;193(3):637-41 [7972800.001]

[Cites] Rofo. 1999 Jul;171(1):38-43 [10464503.001]

[Cites] Radiologe. 2004 Jan;44(1):81-95; quiz 96-7 [14997867.001]

[Cites] Radiologe. 2004 Feb;44(2):164-73 [14991136.001]

[Cites] Neuroimage. 2006 Jun;31(2):531-42 [16478665.001]

[Cites] Radiologe. 2003 Aug;43(8):661-4 [14504767.001]

[Cites] Radiology. 1990 Nov;177(2):401-5 [2217776.001]

[Cites] Radiologe. 2002 Nov;42(11):909-15 [12458444.001]

[Cites] Radiologe. 2005 Jul;45(7):618-32 [15098092.001]

[Cites] Nervenarzt. 2005 Apr;76(4):403-17 [15349736.001]

(PMID = 17505814.001).

[ISSN] 0033-832X

[Journal-full-title] Der Radiologe

[ISO-abbreviation] Radiologe

[Language] ger

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Number-of-references] 21

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Low grade diffuse gliomas: shared cellular composition and morphometric differences.

Low grade diffuse gliomas arising in the brain are challenging to treat because of their ability to infiltrate adjacent tissue.

We attempted to clarify the cellular composition and histopathological features of low grade gliomas by utilizing morphometric and immunohistochemical analyses.

Seventy-eight cases of low grade gliomas were examined including 21 diffuse astrocytomas (DA), 36 oligodendrogliomas (OL), and 21 oligoastrocytomas (OA), based on the WHO classification system.

Double immunostaining revealed that expression of Olig2 and GFAP, and Olig2 and nestin was mutually exclusive in most glioma cells.

We conclude that each glioma include cells expressing GFAP, cells expressing nestin, and cells expressing Olig2 in a characteristic proportion for each tumor type.

We suggest that diffuse gliomas share cellular compositions in different ratios and that they can be distinguished by morphometrical analysis.

[MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glioma / metabolism. Glioma / pathology

[MeSH-minor] Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Fluorescent Antibody Technique. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Image Interpretation, Computer-Assisted. Immunohistochemistry. Intermediate Filament Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis. Nestin. Tumor Suppressor Protein p53 / biosynthesis

MedlinePlus Health Information. consumer health - Brain Tumors.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18282166.001).

[ISSN] 1440-1789

[Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology

[ISO-abbreviation] Neuropathology

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Australia

[Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / OLIG2 protein, human; 0 / Tumor Suppressor Protein p53

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] PTPmu suppresses glioma cell migration and dispersal.

Glioblastomas (GBMs) are the highest grade of primary brain tumors with astrocytic similarity and are characterized by marked dispersal of tumor cells.

PTPmu expression was examined in human GBM, low-grade astrocytoma, and normal brain tissue.

These studies revealed a striking loss of PTPmu protein expression in highly dispersive GBMs compared to less dispersive low-grade astrocytomas and normal brain.

The migration of brain tumor cells was assessed in vitro using a scratch wound assay.

To assess migration, labeled U-87 MG glioma cells were injected into adult rat brain slices, and their movement was followed over time.

Together, these data suggest that loss of PTPmu in human GBMs contributes to tumor cell migration and dispersal, implicating loss of PTPmu in glioma progression.

Genetic Alliance. consumer health - Glioma.

MedlinePlus Health Information. consumer health - Brain Tumors.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Dev Biol. 2004 Jan 1;265(1):23-32 [14697350.001]

[Cites] Mol Cell Biol. 1994 Jan;14(1):1-9 [8264577.001]

[Cites] Cancer Lett. 2004 Apr 8;206(2):181-91 [15013523.001]

[Cites] Mol Cell Biochem. 1993 Nov;127-128:131-41 [7935345.001]

[Cites] J Biol Chem. 1994 Nov 11;269(45):28472-7 [7961788.001]

[Cites] J Cell Biol. 1995 Oct;131(1):251-60 [7559782.001]

[Cites] J Biol Chem. 1997 Mar 14;272(11):7264-77 [9054423.001]

[Cites] J Cell Biol. 1998 Apr 6;141(1):287-96 [9531566.001]

[Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]

[Cites] J Cell Biol. 1999 Mar 22;144(6):1323-36 [10087273.001]

[Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]

[Cites] J Biol Chem. 2005 Nov 11;280(45):37516-25 [16150730.001]

[Cites] J Biol Chem. 2006 Feb 24;281(8):4903-10 [16380380.001]

[Cites] J Neurochem. 2006 Sep;98(5):1497-506 [16923162.001]

[Cites] Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 [17057753.001]

[Cites] J Neurooncol. 2006 Nov;80(2):133-42 [16941076.001]

[Cites] Mol Biol Cell. 2006 Dec;17(12):5141-52 [16987961.001]

[Cites] Mol Cell Neurosci. 2007 Mar;34(3):453-67 [17234431.001]

[Cites] Mol Cell Neurosci. 2007 Mar;34(3):481-92 [17276081.001]

[Cites] Nat Protoc. 2006;1(3):1165-71 [17406399.001]

[Cites] Cancer Res. 2007 Aug 1;67(15):7203-11 [17671188.001]

[Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]

[Cites] Annu Rev Pathol. 2006;1:97-117 [18039109.001]

[Cites] Mol Cancer Res. 2008 Jul;6(7):1106-13 [18644975.001]

[Cites] Nat Rev Mol Cell Biol. 2008 Aug;9(8):603-15 [18648374.001]

[Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]

[Cites] Semin Radiat Oncol. 2001 Apr;11(2):103-12 [11285548.001]

[Cites] J Biol Chem. 2001 May 4;276(18):14896-901 [11278757.001]

[Cites] Cancer Res. 2001 Jun 1;61(11):4612-9 [11389098.001]

[Cites] J Neurosci Res. 2001 Nov 1;66(3):487-96 [11746367.001]

[Cites] Mol Cell Neurosci. 2002 Feb;19(2):292-306 [11860281.001]

[Cites] Neurosurgery. 2003 Jan;52(1):187-96; discussion 196-7 [12493117.001]

[Cites] J Clin Oncol. 2003 Apr 15;21(8):1624-36 [12697889.001]

[Cites] J Neurobiol. 2003 Sep 5;56(3):199-208 [12884260.001]

[Cites] Dev Neurosci. 2003 Mar-Aug;25(2-4):207-16 [12966218.001]

[Cites] Mol Cell Neurosci. 2004 Apr;25(4):558-71 [15080886.001]

[Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11 [15146033.001]

[Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7618-23 [15128949.001]

[Cites] Expert Opin Ther Targets. 2004 Jun;8(3):211-20 [15161428.001]

[Cites] Dev Biol. 2004 Nov 1;275(1):12-22 [15464569.001]

[Cites] Cancer Res. 1984 Feb;44(2):753-60 [6318976.001]

[Cites] Cytometry. 1992;13(1):48-59 [1372202.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]

[Cites] Cell. 1992 Aug 7;70(3):401-10 [1643658.001]

[Cites] J Biol Chem. 1993 Aug 5;268(22):16101-4 [8393854.001]

[Cites] J Cell Biol. 1993 Aug;122(4):961-72 [8394372.001]

[Cites] Breast Cancer Res Treat. 2004 Mar;84(1):13-9 [14999150.001]

(PMID = 19304959.001).

[ISSN] 1523-5866

[Journal-full-title] Neuro-oncology

[ISO-abbreviation] Neuro-oncology

[Language] ENG

[Grant] United States / NINDS NIH HHS / NS / R01 NS051520-04; United States / NEI NIH HHS / EY / P30 EY011373; United States / NINDS NIH HHS / NS / R01 NS051520; United States / NINDS NIH HHS / NS / R01-NS051520; United States / NCI NIH HHS / CA / K08 CA101954; United States / NINDS NIH HHS / NS / NS051520-04; United States / NEI NIH HHS / EY / P30 EY011373-119002; United States / NCI NIH HHS / CA / P20 CA103736; United States / NEI NIH HHS / EY / P30 EY011373-129002; United States / NCI NIH HHS / CA / P30 CA043703; United States / NEI NIH HHS / EY / P30 EY011373-139002; United States / NCI NIH HHS / CA / T32 CA059366; United States / NINDS NIH HHS / NS / NS051520-02; United States / NINDS NIH HHS / NS / NS051520-01A1; United States / NEI NIH HHS / EY / EY011373-139002; United States / NIGMS NIH HHS / GM / T32-GM007250; United States / NEI NIH HHS / EY / P30-EY11373; United States / NEI NIH HHS / EY / EY011373-119002; United States / NINDS NIH HHS / NS / NS051520-03; United States / NINDS NIH HHS / NS / R01 NS051520-02; United States / NINDS NIH HHS / NS / R01 NS051520-01A1; United States / NEI NIH HHS / EY / EY011373-129002; United States / NCI NIH HHS / CA / K08-CA101954; United States / NCI NIH HHS / CA / R01-CA116257; United States / NCI NIH HHS / CA / P30-CA043703; United States / NCI NIH HHS / CA / T32-CA059366; United States / NCI NIH HHS / CA / R01 CA116257; United States / NIGMS NIH HHS / GM / T32 GM007250; United States / NINDS NIH HHS / NS / R01 NS051520-03; United States / NCI NIH HHS / CA / P20-CA103736

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 2

[Other-IDs] NLM/ PMC2802397